DOCSLIB.ORG

Handbook of Pediatric Surgical Critical Care

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Handbook of Pediatric Surgical Critical Care Handbook of Pediatric TM Surgical Critical Care First Edition 2013 from the Surgical Critical Care Task Force of the American Pediatric Surgical Association April 2013 Editor-in-Chief: Marjorie J. Arca, MD ©2013, American Pediatric Surgical Association EDITOR-IN-CHIEF CONTACT PERSON MARJORIE J. ARCA, MD PROFESSOR DEPARTMENTS OF SURGERY AND PEDIATRICS MEDICAL COLLEGE OF WISCONSIN [email protected] +1-414-266-6550 CONTRIBUTORS Marjorie J. Arca, MD Professor of Surgery Division of Pediatric Surgery, Department of Surgery Medical College of Wisconsin Milwaukee, WI Oxygen Kinetics, Mechanical Ventilation, The Surgical Neonate, Fluid/Elextrolytes/Nutrition, Transfustion and Anticoagulation, Cardiology Basics Felix C Blanco, MD Transplant Surgery Fellow University of Minnesota Medical Center Minneapolis, MN Renal Physiology, Renal Failure and Renal Replacement Therapy David W. Bliss, MD Associate Professor of Surgery Department of Surgery Children’s Hospital of Los Angeles Los Angeles, CA Monitoring in the ICU Anthony C Chin, MD Assistant Professor of Surgery Ann & Robert H. Lurie Children’s Hospital of Chicago Northwestern University Chicago, IL Pediatric Thoracic Trauma Utpala Das, MD Associate Professor of Pediatrics Children’s Hospital of Wisconsin Medical College of Wisconsin Milwaukee. WI Ventilation in the NICU Medical Conditions in the NICU Samir Gadepalli, MD Assistant Professor of Surgery Division of Pediatric Surgery, Department of Surgery University of Michigan Ann Arbor, MI Extracorporeal Membrane Oxygenation/Extracorporeal Lung Support, Sepsis Alessandra Gasior, DO Pediatric Surgical Critical Care Fellow Children’s Mercy Hospital Kansas City, MO Pediatric Neurotrauma Raquel Gonzalez, MD Assistant Professor of Surgery Department of Surgery Wayne State University School of Medicine Children’s Hospital of Michigan Detroit, MI Burns Ronald B. Hirschl, MD Professor of Surgery, Surgeon in Chief Division of Pediatric Surgery, Department of Surgery University of Michigan Ann Arbor, MI Extracorporeal Membrane Oxygenation/Extracorporeal Lung Support, Sepsis Aaron Jensen, MD, MEd Fellow in Pediatric Surgery Children’s Hospital of Los Angeles Los Angeles, CA ICU Monitoring David Juang, MD Director, Trauma, Burns and Critical Care Director, Pediatric Surgical Critical Care Fellowship Children’s Mercy Hospital Assistant Professor of Surgery University of Missouri - Kansas City Kansas City, MO Pediatric Neurotrauma Brian Kenney, MD Associate Professor of Surgery Division of Pediatric Surgery, Department of Surgery Nationwide Children’s Hospital The Ohio State University Columbus, OH Fluids and Nutrition in the ICU II Jennifer Liedel, MD Assistant Professor of Pediatrics Children’s Hospital of Wisconsin Medical College of Wisconsin Milwaukee. WI Ventilation in the NICU Medical Conditions in the NICU Peter C. Minneci, MD Assistant Professor of Surgery Center for Surgical Outcomes Research Division of Pediatric Surgery, Department of Surgery Nationwide Children’s Hospital The Ohio State University Columbus, OH A Primer on Quality Improvement in the ICU Daniel J. Ostlie, MD Surgeon-in-Chief, American Family Children's Hospital Chair, Pediatric Surgery Department of Surgery University of Wisconsin Madison, WI Pediatric Abdominal Trauma Pramod Puligandla, MD Associate Professor of Pediatric Surgery, Surgery, and Pediatrics Program Director, Pediatric Surgery Attending Staff, Pediatric General and Thoracic Surgery Attending Staff, Pediatric Critical Care Medicine Montreal Children's Hospital, McGill University Health Centre Montreal, QC Canada Shock, Low Cardiac Output, and Inotropic Support Faisal G. Qureshi, MD Assistant Professor of Pediatrics, Surgery George Washington University Children’s National Medical Center Washington, DC Renal Physiology, Renal Failure and Renal Replacement Therapy Robert L. Ricca, MD Assistant Professor of Surgery, USUHS Naval Medical Center Portsmouth Portsmouth, VA Transfusion and Anticoagulation III Anna Ruzic, MD Pediatric Surgery Fellow University of Florida, Gainesville Gainesville, FL Extracorporeal Membrane Oxygenation/Extracorporeal Lung Support, Sepsis Christina M. Shanti, MD Medical Director, Burn Program Department of Surgery Wayne State University School of Medicine Children’s Hospital of Michigan Detroit, MI Burns Sifrance Tran MD Pediatric Surgical Critical Care Fellow Ann & Robert H. Lurie Children’s Hospital of Chicago Northwestern University Chicago, IL Pediatric Thoracic Trauma Martin Wakeham, MD Associate Professor of Pediatrics Medical College of Wisconsin Milwaukee. WI Mechanical Ventilation Jill Zalieckas, MD, MPH Assistant Professor of Surgery Boston, MA Sedation and Analgesia Christopher Weldon, MD, PhD Assistant Professor of Surgery Boston Children’s Hospital Boston, MA Sedation and Analgesia IV NOTICE The authors, editors, and APSA disclaim any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use or application of any of the contents of this volume. While authors and editors have made every effort to create guidelines that should be helpful, it is impossible to create a text that covers every clinical situation that may arise in regards to either diagnosis and/or treatment. Authors and editors cannot be held responsible for any typographic or other errors in the printing of this text. Any dosages or instructions in this text that are questioned should be cross-referenced with other sources. Attending physicians, residents, fellows, students, and providers using this handbook in the treatment of infants should recognize that this text is not meant to be a replacement for discourse or consultations with the attending and consulting staff. Management strategies and styles discussed within this text are neither binding nor definitive and should not be treated as a collection of protocols. I would like to extend my gratitude to contributors to this first edition of the Handbook of Pediatric Surgical Critical Care. Feedback regarding this edition as well as future editions is not only welcome, but also greatly appreciated. Marjorie Arca, MD April 2014 V INTRODUCTION To the Members of APSA: Two years ago, a group of pediatric surgeons with interest and training in surgical critical care met to cultivate and enhance our collective experience within pediatric surgery. We felt that as pediatric surgeons, our voices remain unique, relevant and valuable in caring for our patients, in the training of our fellows, and in informing our colleagues. One of the first projects that we embarked upon is a Handbook of Pediatric Surgical Critical Care. We felt that this would create a uniform basis for our critical care and pediatric surgical curriculum. We also thought that this handbook would provide another dimension to the training for neonatology, pediatric critical care, and adult critical care fellows. Finally, we felt that this project may be helpful to our colleagues, who already in practice, as a point of reference in the care of the most complex surgical patients. I personally would like to thank all the contributors to this seminal project. We also thank APSA Staff for helping us put this project together. We would also like to thank APSA for allowing the website to be the platform for dissemination of the handbook. The authors of this handbook welcome any and all comments from the membership. Marjorie J. Arca, MD Editor VI TABLE OF CONTENTS 1. Oxygen Kinetics ........................................................................................................ 8 2. The Pediatric Airway ............................................................................................... 16 3. Mechanical Ventilation…..……………………………………………...…………………20 4. Ventilation in the NICU ............................................................................................ 34 5. Extracorporeal Membrane Oxygenation/Extracorporeal Lung Support……..……… 53 6. Monitoring in the ICU .............................................................................................. 83 7. Shock, Low Cardiac Output and Inotropic Support ................................................ 106 8. Sepsis .................................................................................................................. 121 9. Fluid, Electrolytes and Nutrition ............................................................................ 152 10. Renal Physiology, Acute Renal Failure, and Renal Replacement Therapy in Children ................................................................................................................................... 176 11. Transfusion and Anticoagulation ........................................................................... 214 12. Sedation and Analgesia ....................................................................................... 232 13. Pediatric Neurotrauma ......................................................................................... 275 14. Pediatric ThoracicTrauma .................................................................................... 292 15. Pediatric Abdominal Trauma ................................................................................ 334 16. Pediatric Burns ..................................................................................................... 357 17. The Surgical Neonate .......................................................................................... 371 18. Medical Conditions in the Neonatal ICU ............................................................... 415
Load more

Recommended publications
  • 204508S000lbl.Pdf
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ____________________CONTRAINDICATIONS____________________ CLINOLIPID injection safely and effectively. See full prescribing • Known hypersensitivity to egg and soybean proteins, the lipid emulsion information for CLINOLIPID injection. and/or excipients. (4) • Severe hyperlipidemia or severe disorders of lipid metabolism. (4) CLINOLIPID (Lipid Injectable Emulsion) for intravenous use Initial U.S. Approval: 1975 ________________WARNINGS AND PRECAUTIONS_______________ • Preterm infants have poor clearance of intravenous lipid emulsion. (5.1) WARNING: DEATH IN PRETERM INFANTS • Monitor for signs or symptoms of hypersensitivity reactions. (5.2) See full prescribing information for complete boxed warning • Monitor for signs and symptoms of infection, fat overload, and refeeding • Deaths in preterm infants have been reported in literature. (5.1, complications. (5.3, 5.4, 5.5) 8.4) • Frequent clinical and laboratory determinations are necessary. (5.6) • Autopsy findings included intravascular fat accumulation in the lungs. (5.1, 8.4) __________________ADVERSE REACTIONS__________________ • Preterm and low birth weight infants have poor clearance of The most common (5%) adverse drug reactions from clinical trials were intravenous lipid emulsion and increased free fatty acid plasma nausea and vomiting, hyperlipidemia, hyperglycemia, hypoproteinemia and levels following lipid emulsion infusion. (5.1, 8.4) abnormal liver function tests. (6.1) __________________INDICATIONS AND USAGE___________________ To report SUSPECTED ADVERSE REACTIONS, contact Baxter CLINOLIPID injection is a lipid emulsion indicated in adults for parenteral Healthcare at 1-866-888-2472 or FDA at 1-800-FDA-1088 or nutrition providing a source of calories and essential fatty acids when oral or www.fda.gov/medwatch enteral nutrition is not possible, insufficient, or contraindicated.
    [Show full text]
  • Criteria for Critical Care of Infants and Children: PICU Admission, Discharge, and Triage Practice Statement and Levels of Care Guidance Benson S
    POLICY STATEMENT Organizational Principles to Guide and Define the Child Health Care System and/or Improve the Health of all Children Executive Summary: Criteria for Critical Care of Infants and Children: PICU Admission, Discharge, and Triage Practice Statement and Levels of Care Guidance Benson S. Hsu, MD, MBA, FAAP,a Vanessa Hill, MD, FAAP,b Lorry R. Frankel, MD, FCCM,c Timothy S. Yeh, MD, MCCM,d Shari Simone, CRNP, DNP, FCCM, FAANP, FAAN,e Marjorie J. Arca, MD, FACS, FAAP,f Jorge A. Coss-Bu, MD,g Mary E. Fallat, MD, FACS, FAAP,h Jason Foland, MD,i Samir Gadepalli, MD, MBA,j Michael O. Gayle, BS, MD, FCCM,k Lori A. Harmon, RRT, MBA, CPHQ,l Christa A. Joseph, RN, MSN,m Aaron D. Kessel, BS, MD,n Niranjan Kissoon, MD, MCCM,o Michele Moss, MD, FCCM,p Mohan R. Mysore, MD, FAAP, FCCM,q MicheleC . Papo, MD, MPH, FCCM,r Kari L. Rajzer-Wakeham, CCRN, MSN, PCCNP, RN,s Tom B. Rice, MD,t David L. Rosenberg, MD, FAAP, FCCM,u Martin K. Wakeham, MD,v,t Edward E. Conway, Jr, MD, FCCM, MS,w Michael S.D. Agus, MD, FAAP, FCCMx This is an executive summary of the 2019 update of the 2004 guidelines and levels of abstract care for PICU. Since previous guidelines, there has been a tremendous a transformation of Pediatric Critical Care Medicine with advancements in pediatric Pediatric Critical Care, Sanford School of Medicine, University of South Dakota, Vermillion, South Dakota; bHospital Medicine, Baylor cardiovascular medicine, transplant, neurology, trauma, and oncology as well as College of Medicine and Children’s Hospital of San Antonio, San improvements of care in general PICUs.
    [Show full text]
  • Care of the Pediatric Patient in Surgery: Neonatal Through Adolescence ”
    CARE OF THE PEDIATRIC PATIENT IN SURGERY : NEONATAL THROUGH ADOLESCENCE 1961 1961 CARE OF THE PEDIATRIC PATIENT IN SURGERY : NEONATAL THROUGH ADOLESCENCE STUDY GUIDE Disclaimer AORN and its logo are registered trademarks of AORN, Inc. AORN does not endorse any commercial company’s products or services. Although all commercial products in this course are expected to conform to professional medical/nursing standards, inclusion in this course does not constitute a guarantee or endorsement by AORN of the quality or value of such products or of the claims made by the manufacturers. No responsibility is assumed by AORN, Inc, for any injury and/or damage to persons or property as a matter of product liability, negligence or otherwise, or from any use or operation of any standards, recommended practices, methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the health care sciences in particular, independent verification of diagnoses, medication dosages, and individualized care and treatment should be made. The material contained herein is not intended to be a substitute for the exercise of professional medical or nursing judgment. The content in this publication is provided on an “as is” basis. TO THE FULLEST EXTENT PERMITTED BY LAW, AORN, INC, DISCLAIMS ALL WARRANTIES, EITHER EXPRESSED OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE. This publication may be photocopied for noncommercial purposes of scientific use or educational advancement. The following credit line must appear on the front page of the photocopied document: Reprinted with permission from The Association of periOperative Registered Nurses, Inc.
    [Show full text]
  • Chemical Pancreatectomy Treats Chronic Pancreatitis While Preserving Endocrine Function in Preclinical Models
    Chemical pancreatectomy treats chronic pancreatitis while preserving endocrine function in preclinical models Mohamed Saleh, … , Krishna Prasadan, George Gittes J Clin Invest. 2020. https://doi.org/10.1172/JCI143301. Research In-Press Preview Endocrinology Gastroenterology Chronic pancreatitis affects over 250,000 people in the US and millions worldwide. It is associated with chronic debilitating pain, pancreatic exocrine failure, high-risk of pancreatic cancer, and usually progresses to diabetes. Treatment options are limited and ineffective. We developed a new potential therapy, wherein a pancreatic ductal infusion of 1-2% acetic acid in mice and non-human primates resulted in a non-regenerative, near-complete ablation of the exocrine pancreas, with complete preservation of the islets. Pancreatic ductal infusion of acetic acid in a mouse model of chronic pancreatitis led to resolution of chronic inflammation and pancreatitis-associated pain. Furthermore, acetic acid-treated animals showed improved glucose tolerance and insulin secretion. The loss of exocrine tissue in this procedure would not typically require further management in patients with chronic pancreatitis because they usually have pancreatic exocrine failure requiring dietary enzyme supplements. Thus, this procedure, which should be readily translatable to humans through an endoscopic retrograde cholangiopancreatography (ERCP), may offer a potential innovative non-surgical therapy for chronic pancreatitis that relieves pain and prevents the progression of pancreatic diabetes. Find the latest version: https://jci.me/143301/pdf Chemical pancreatectomy treats chronic pancreatitis while preserving endocrine function in preclinical models Authors: Mohamed Saleh1,2, *Kartikeya Sharma1, *Ranjeet Kalsi1, Joseph Fusco1, Anuradha Sehrawat1, Jami L. Saloman3, Ping Guo4, Ting Zhang 1, Nada Mohamed1, Yan Wang1, Krishna Prasadan1, George K.
    [Show full text]
  • Liposomes to Augment Dialysis in Preclinical Models: a Structured Review
    pharmaceutics Review Liposomes to Augment Dialysis in Preclinical Models: A Structured Review Kevin Hart 1,*, Martyn Harvey 2, Mingtan Tang 3 , Zimei Wu 3 and Grant Cave 1 1 Intensive Care Unit, Hawkes Bay District Health Board, Hastings 9014, New Zealand; [email protected] 2 Waikato Hospital Emergency Department, Waikato District Health Board, Hamilton 3240, New Zealand; [email protected] 3 Faculty of Medicine and Health Sciences, School of Pharmacy, University of Auckland, Auckland 1023, New Zealand; [email protected] (M.T.); [email protected] (Z.W.) * Correspondence: [email protected] Abstract: In recent years, a number of groups have been investigating the use of “empty” liposomes with no drug loaded as scavengers both for exogenous intoxicants and endogenous toxic molecules. Preclinical trials have demonstrated that repurposing liposomes to sequester such compounds may prove clinically useful. The use of such “empty” liposomes in the dialysate during dialysis avoids recognition by complement surveillance, allowing high doses of liposomes to be used. The “reach” of dialysis may also be increased to molecules that are not traditionally dialysable. We aim to review the current literature in this area with the aims of increasing awareness and informing further research. A structured literature search identified thirteen papers which met the inclusion criteria. Augmenting the extraction of ammonia in hepatic failure with pH-gradient liposomes with acidic centres in peritoneal dialysis is the most studied area, with work progressing toward phase one trials. Liposomes used to augment the removal of exogenous intoxicants and protein- Citation: Hart, K.; Harvey, M.; Tang, bound uraemic and hepatic toxins that accumulate in these organ failures and liposome-supported M.; Wu, Z.; Cave, G.
    [Show full text]
  • PEDIATRIC SURGERY WELCOME to PEDIATRIC SURGERY This Is a Busy Surgical Service with Lots to See and Do
    Medical Students Guide to PEDIATRIC SURGERY WELCOME TO PEDIATRIC SURGERY This is a busy surgical service with lots to see and do. Our goal is to integrate you into the service so that you can get the best experience possible during your time here. This guide details the structure of our service along with some pointers to help get you up and running. DAILY SCHEDULE 6 a.m. Morning rounds * 6th fl, East, NICU front desk 7 a.m. Radiology rounds 2nd fl, East, Radiology Body reading room 7:30 a.m. OR start (starts at 8:30 a.m. on Thurs) 2nd fl, Main 8 a.m. - 4 p.m. Clinic 4th fl Main, Suite 4400 5 p.m. Afternoon rounds 5th fl, East (outside room 501) *Sat & Sun rounds start at 7 or 7:30 a.m., confirm time with team ROTATION SCHEDULE Your rotation will start on August 31 and will end on September 18, 2020. See attached schedule. TEACHING SESSIONS: General surgery clinic days are Mondays, 1 Tuesdays, Thursdays and Fridays in Suite 4400 7:00 – 9:00 A.M. Telehealth clinics are generally scheduled at Thursday 2 the end of clinic Morning Pediatric Surgery Conference Guzzetta Library General surgery elective OR days by faculty 3 members are each day. 3:00 – 5:30 P.M. generally between Tuesdays and Fridays 4 The add-on room runs each day. Medical student lectures Guzzetta Library Your schedule will include time spent in the 5 surgery clinic, in the OR, with the consult resident, and with the surgeon of the day.
    [Show full text]
  • Pediatric Surgery What You Need to Know
    Pediatric Surgery What you need to know Norton Women’s & Children’s Hospital Welcome to the Pediatric Billing Surgery Center Most bills are submitted to your insurance company for payment. Our registration staff will ask you for your Norton Women’s & Children’s Hospital insurance information. Our staff of pediatric health care professionals understands the specialized care that is so important for children. If for some reason we are unable to submit claims to your Learning about your child’s surgery will help you and your insurance company for you, we will inform you immediately. child feel less anxious. In this instance, we will offer you all the necessary information you need regarding the different payment plans We’ve developed this brochure to answer some of your available to make the process as easy as possible. questions and give you important information before bringing your child to the Pediatric Surgery Center. Please After your child’s procedure is scheduled, attempts are read it carefully. It is important to us that your child has a made to verify your insurance coverage and copayment. It safe and pleasant surgical experience. is your responsibility to pay the copayment amount. There are many different kinds of insurance coverage, and some We know that no procedure is small or routine when it plans cover more than others. You may want to check with comes to your child. We consider you and your child as your insurance company regarding the coverage provided essential members of the health care team, and we promise by your individual plan.
    [Show full text]
  • 6 Literaturverzeichnis
    6 Literaturverzeichnis 6 Literaturverzeichnis Adam, A., Lederer, E., Muramyl peptides: Immunomodulators, sleep factors and vitamins. Med. Res. Rev. 4, 111-153, 1984. Akao, T., Correlation between physicochemical characteristics of synthetic cationic am- phiphiles and their DNA transfection ability. Bull. Chem. Soc. Jpn. 64, 3677-3681, 1991. Allison, A.C., Byars, N.E., Immunological adjuvants: desirable properties and side-effects. Mol. Immunol. 28, 279-284, 1991. Alving, C.R., Verma, J.N., Rao, U., Krzych, U., Amselem, S. Green, S.M., Wassef, N.M., Liposomes containing lipid A as potent non-toxic adjuvant. Res. Immunol. 143, 197-198, 1992. Alving, C.R., Lipopolysaccharide, lipid A and liposomes containing lipid A as immuno- logic adjuvants. Immunobiology 187, 430-446, 1993. Anderson, W.F., Human gene therapy. Nature 392, 25-30, 1998. Aprile, M.A., Wardlaw, A.C.,Aluminum compounds as adjuvants for vaccines and toxoids in man: a review. Can. J. Publ. Hlth 57, 343-354, 1966. Avrameas, S., Guilbert, B., Dosage enzymoimmunologique de protéine à l'aide d'immu- noadsorbants et d'antigènes marqués aux enzymes. C. R. Acad. Sci.(Paris) 273, 2705-2707, 1971. Bally, M.B., Harvie, P., Wong, F.M.P., Kong, S., Wasan, E.K., Reimer, D.L., Biological barriers to cellular delivery of lipid-based DNA carriers. Adv. Drug Deliv. Rev. 38, 291- 315, 1999. Behr, J.P., Gene transfer with synthetic cationic amphiphiles: Prospects for Gene Therapy. Bioconj. Chem. 5, 382-389, 1994. Binnig, G., Quate, C.F., Gerber, C., Atomic force microscopy. Phys. Rev. Lett. 56, 930- 933, 1986. Biocompare.com, Auflistung kommerzieller liposomaler Transfektiosagenzien unter http://biocompare.com Birchall, J.C., Kellaway, I.W., Mills, S.N., Physico-chemical characterisation and trans- fection efficiency of lipid-based gene delivery complexes.
    [Show full text]
  • Treatment for Calcium Channel Blocker Poisoning: a Systematic Review
    Clinical Toxicology (2014), 52, 926–944 Copyright © 2014 Informa Healthcare USA, Inc. ISSN: 1556-3650 print / 1556-9519 online DOI: 10.3109/15563650.2014.965827 REVIEW ARTICLE Treatment for calcium channel blocker poisoning: A systematic review M. ST-ONGE , 1,2,3 P.-A. DUB É , 4,5,6 S. GOSSELIN ,7,8,9 C. GUIMONT , 10 J. GODWIN , 1,3 P. M. ARCHAMBAULT , 11,12,13,14 J.-M. CHAUNY , 15,16 A. J. FRENETTE , 15,17 M. DARVEAU , 18 N. LE SAGE , 10,14 J. POITRAS , 11,12 J. PROVENCHER , 19 D. N. JUURLINK , 1,20,21 and R. BLAIS 7 1 Ontario and Manitoba Poison Centre, Toronto, ON, Canada 2 Institute of Medical Science, University of Toronto, Toronto, ON, Canada 3 Department of Clinical Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada 4 Direction of Environmental Health and Toxicology, Institut national de sant é publique du Qu é bec, Qu é bec, QC, Canada 5 Centre Hospitalier Universitaire de Qu é bec, Qu é bec, QC, Canada 6 Faculty of Pharmacy, Université Laval, Qu é bec, QC, Canada 7 Centre antipoison du Qu é bec, Qu é bec, QC, Canada 8 Department of Medicine, McGill University, Montr é al, QC, Canada 9 Toxicology Consulting Service, McGill University Health Centre, Montr é al, QC, Canada 10 Centre Hospitalier Universitaire de Qu é bec, Qu é bec, QC, Canada 11 Centre de sant é et services sociaux Alphonse-Desjardins (CHAU de Lévis), L é vis, QC, Canada 12 Department of Family Medicine and Emergency Medicine, Universit é Laval, Québec, QC, Canada 13 Division de soins intensifs, Universit é Laval, Qu é bec, QC, Canada 14 Populations
    [Show full text]
  • Role of IV Lipid Emulsion Antidote
    Vet Times The website for the veterinary profession https://www.vettimes.co.uk Role of IV lipid emulsion antidote Author : Lotfi El Bahri Categories : General, Vets Date : March 28, 2016 The first animal reports suggesting an increased rate of recovery from barbiturate-induced CNS depression with lipid infusion were published in 19621. Encouraging results of animal studies, and successful use in human case reports, have demonstrated lipid emulsion has a potential role in the treatment of lipophilic molecules intoxications2. Background Image: Fotolia/Sherry Young. Lipid emulsion – also referred to as intravenous lipid emulsion (ILE), lipid resuscitation therapy, intravenous lipid emulsion rescue and intravenous fat emulsion – is known as a component of parenteral nutrition (ILE 30 per cent). It is also used as a carrier for lipid soluble drugs, such as propofol, etomidate and diazepam3,4. ILE is an injectable oil in water emulsion mixing long-chain and medium-chain triglycerides, or a combination of both, purified egg phospholipids as emulsifiers, anhydrous glycerol for the adjustment of tonicity, water for injection (with a pH of six to nine) and contains no preservatives3,4. ILE is available in concentrations ranging from 10 per cent to 30 per cent. Although purified 1 / 6 soybean oil is most commonly used as the major source of triglycerides, other sources are also used (such as olive oil and fish oil)3,4. The United States Pharmacopeia and the European Pharmacopoeia standards have established a globule size distribution limit for all lipid emulsions where the mean droplet size must be lower than 500 nanometres, and the percentage of fat larger than 5µm must be lower than 0.05 per cent5.
    [Show full text]
  • Nanoparticle System Based on Amino-Dextran As a Drug Delivery Vehicle: Immune-Stimulatory Cpg-Oligonucleotide Loading and Delivery
    pharmaceutics Article Nanoparticle System Based on Amino-Dextran as a Drug Delivery Vehicle: Immune-Stimulatory CpG-Oligonucleotide Loading and Delivery Hien V. Nguyen 1,2, Katrin Campbell 2 , Gavin F. Painter 3, Sarah L. Young 4 and Greg F. Walker 1,* 1 School of Pharmacy, University of Otago, Dunedin 9016, New Zealand; [email protected] 2 Department of Pathology, University of Otago, Dunedin 9016, New Zealand; [email protected] 3 The Ferrier Research Institute, Victoria University of Wellington, Wellington 5040, New Zealand; [email protected] 4 School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney 2006, NSW, Australia; [email protected] * Correspondence: [email protected]; Tel.: +64-3-479-7133 Received: 11 November 2020; Accepted: 25 November 2020; Published: 27 November 2020 Abstract: The aim of this study is to prepare and characterize an amino-dextran nanoparticle (aDNP) platform and investigate two loading strategies for unmethylated cytosine-phosphate-guanine (CpG) oligonucleotide. aDNP was prepared by desolvation of amino-dextran followed by the chemical crosslinking of amino groups. Size, surface charge, and surface morphology of aDNP was determined by dynamic light scattering and transmission electron microscopy. CpG was either loaded onto aDNP by adsorption (CpG-adsorbed-aDNP) or conjugated to aDNP (CpG-conjugated-aDNP). In vitro cytokine production by bone marrow-derived dendritic cells (BMDCs) was measured by flow cytometry. aDNPs size and zeta potential could be controlled to produce uniform particles in the size range of 50 to 300 nm, surface charge of 16.5 to +14 mV, and were spherical in shape.
    [Show full text]
  • Intravenous Lipid Emulsions in the Treatment of Essential Fatty Acid Deficiency: Studies in Young Pigs
    ANDERSEN ET AL. 003 1-3998/84/18 12-1 350$02.00/0 PEDIATRIC RESEARCH Vol. 18, No. 12, 1984 Copyright O 1984 International Pediatric Research Foundation, Inc. Printed in U.S.A. Intravenous Lipid Emulsions in the Treatment of Essential Fatty Acid Deficiency: Studies in Young Pigs DEAN W. ANDERSEN, L. J. FILER, JR., AND LEWIS D. STEGINK The University of Iowa, Departments of Pediatrics and Biochemistry, Iowa City, Iowa 52242 ABSTRACT. Essential fatty acid deficiency (EFAD) oc- fed fat-free diets usually fast overnight, causing triglyceride mo- curs in infants fed fat-free mixtures of glucose and amino bilization from adipose tissue to supply energy needs. Essential acids. Although infusion of lipid emulsion rapidly reverses fatty acids are released to the circulation as part of this process, clinical symptoms, little is known about effects on tissue supplying requirements. When a nutritional regimen that does fatty acids. To study this question, five groups (n = 41 not provide sufficient energy is fed, a similar process occurs. group) of neonatal pigs were studied. Three groups (I, 11, During eucaloric or hypercaloric total parenteral or enteral and V) were made EFAD by feeding diets without essential nutrition, total energy requirements are supplied by constant fatty acids (EFA) for days 5 to 33 of life. Groups 111 and infusion of glucose-amino acid mixtures in amounts equal to or IV were fed a control diet. By 33 days, animals fed the greater than energy requirements. The increased insulin levels deficient diet showed clinical symptoms and biochemical produced by such infusions decrease adipose tissue lipase activity, signs of EFAD.
    [Show full text]